Colin is a strategic commercialization ally with a powerful combination of expertise in scientific research and business development. He brings over a decade of experience in pharmaceutical marketing and contract research industries, as well as a highly analytical and collaborative approach to building mutually-beneficial business relationships. Colin has been an active member of the OPMA since 2013, joined the Board of Directors in 2016 and served as President in 2018.